| COVID-19: drug targets and potential treatments C Gil, T Ginex, I Maestro, V Nozal, L Barrado-Gil, MÁ Cuesta-Geijo, ... Journal of medicinal chemistry 63 (21), 12359-12386, 2020 | 442 | 2020 |
| TDP-43: a key therapeutic target beyond amyotrophic lateral sclerosis V Palomo, C Tosat-Bitrian, V Nozal, S Nagaraj, A Martin-Requero, ... ACS chemical neuroscience 10 (3), 1183-1196, 2019 | 57 | 2019 |
| Protein kinase inhibitors for amyotrophic lateral sclerosis therapy V Palomo, V Nozal, E Rojas‐Prats, C Gil, A Martinez British Journal of Pharmacology 178 (6), 1316-1335, 2021 | 43 | 2021 |
| Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases V Nozal, A Martinez European Journal of Medicinal Chemistry 161, 39-47, 2019 | 40 | 2019 |
| TDP-43 modulation by tau-tubulin kinase 1 inhibitors: A new avenue for future amyotrophic lateral sclerosis therapy V Nozal, L Martínez-González, M Gomez-Almeria, C Gonzalo-Consuegra, ... Journal of Medicinal Chemistry 65 (2), 1585-1607, 2022 | 33 | 2022 |
| Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical in silico/in vitro screening methods T Ginex, U Garaigorta, D Ramírez, V Castro, V Nozal, I Maestro, ... Pharmaceuticals 14 (4), 332, 2021 | 28 | 2021 |
| From kinase inhibitors to multitarget ligands as powerful drug leads for Alzheimer's disease using protein‐templated synthesis V Nozal, A García‐Rubia, EP Cuevas, C Pérez, C Tosat‐Bitrián, ... Angewandte Chemie 133 (35), 19493-19503, 2021 | 27 | 2021 |
| Improved controlled release and brain penetration of the small molecule S14 using PLGA nanoparticles V Nozal, E Rojas-Prats, I Maestro, C Gil, DI Perez, A Martinez International Journal of Molecular Sciences 22 (6), 3206, 2021 | 25 | 2021 |
| Increasing brain permeability of PHA-767491, a cell division cycle 7 kinase inhibitor, with biodegradable polymeric nanoparticles E Rojas-Prats, C Tosat-Bitrián, L Martínez-González, V Nozal, DI Pérez, ... Pharmaceutics 13 (2), 180, 2021 | 18 | 2021 |
| TTBK1 and CK1 inhibitors restore TDP-43 pathology and avoid disease propagation in lymphoblast from Alzheimer’s disease patients L Martinez-Gonzalez, EP Cuevas, C Tosat-Bitrián, V Nozal, C Gil, ... Frontiers in Molecular Neuroscience 16, 1243277, 2023 | 3 | 2023 |
| From kinase inhibitors to multitarget ligands as powerful drug leads for Alzheimer’s disease using protein-templated synthesis A Martínez Gil, V Nozal, A García-Rubia, EP Cuevas, C Pérez, V Palomo, ... John Wiley & Sons, 2021 | 1 | 2021 |
| Improved linkage design for the discovery of multitarget ligands as powerful drugs for Alzheimer’s disease V Nozal, A García-Rubia, C Pérez, A Martínez Gil, V Palomo Real Academia Nacional de Farmacia (España), 2019 | 1 | 2019 |
| タウ-チューブリンキナーゼ (TTBK) 阻害化合物 A Martínez Gil, C Gil, V Nozal, V Palomo, Á Martín-Requero, ... | | 2024 |
| Designing multitarget ligands for neurodegenerative diseases with improved permeability trough PLGA nanoencapsulation V Nozal, P Fernández-Gómez, A García-Rubia, L Martínez-González, ... Biomedicine & Pharmacotherapy 175, 116626, 2024 | | 2024 |
| Tau-tubulin kinase (TTBK) inhibitor compounds A Martínez Gil, C Gil, V Nozal, V Palomo, Á Martín-Requero, ... | | 2024 |
| Compuestos inhibidores de la quinasa de tau y tubulina (TTBK) A Martínez Gil, C Gil, V Nozal, V Palomo, Á Martín-Requero, ... | | 2023 |
| Modulación de la neurodegeneración con nuevas aproximaciones multidiana: diseño y síntesis de compuestos innovadores V Nozal CSIC-Centro de Investigaciones Biológicas Margarita Salas (CIB), 2022 | | 2022 |
| P34 Measuring protein aggregation in lymphoblasts from als patients with a turbidometric assay C Pérez de la Lastra, C Tosat-Bitrian, V Nozal, A Martínez Gil, ... Sociedad Española de Química Terapéutica, 2021 | | 2021 |
| O2 Improved controlled release and brain penetration of small molecules with therapeutic potential using PLGA nanoparticles V Nozal, E Rojas-Prats, DI Pérez, C Gil, A Martínez Gil Sociedad Española de Química Terapéutica, 2021 | | 2021 |
| Protein kinase inhibitors for amyotrophic lateral sclerosis therapy (vol 178, pg 1316, 2021) V Palomo, V Nozal, E Rojas-Prats, C Gil, A Martinez BRITISH JOURNAL OF PHARMACOLOGY 178 (10), 2162-2162, 2021 | | 2021 |
